Proteomics in drug development
Protein biomarker studies accelerate drug discovery and development. They can increase the probability of successfully implementing new therapies by enabling deep knowledge of the biology underlying human disease and providing actionable insights to guide key decision-making.
Illustration: Ibrahim Rayintakath
Addressing key challenges
Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Olink’s PEA technology is increasingly used to identify new drug targets and analyze samples from clinical trials to stratify patient populations, predict responses, and provide insights into the biology of disease and drug modes of action.
Robust drug target selection
Identify protein biomarkers that are causal for diseases.
Identify non-invasive biomarkers
Save time/cost/inconvenience of invasive sampling (tissue biopsies, imaging etc).
Pre-stratify patients for smaller clinical trials
Reduce the size and cost of clinical trials by identifying likely responders during the selection of enrollees.
Actionable insights into drug mode of action
Characterize mode of drug action through deep understanding of disease biology.
Identify predictive markers for drug response
Successful application of drugs to the right patients.
Repurpose drugs for new indications
New applications through deeper understanding of disease patho-mechanisms.
Selected interview
Dr. Chris Whelan (Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project) discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success.
Working with Olink
See what some leading scientists in their fields have to say about their experiences working with Olink and our PEA solutions for drug development.
Selected reading
Olink’s PEA technology is advancing drug repurposing efforts. Studies highlight its role in identifying biomarkers for heart failure (EMPEROR study), predicting rheumatoid arthritis treatment responses, and enabling early cancer detection and patient stratification, enhancing drug development and precision medicine.
A flexible platform that accelerates your research
Olink’s scalable technology provides optimized solutions for every stage of the biomarker workflow, from high-throughput discovery through validation and clinical utility.
Get help choosing. Talk to a Specialist
Olink Explore HT
Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.
Proteins
5,400+ With proven specificity
Sample
2 µL Plasma, serum & more
Olink Flex
Run individually tailored studies by combining up to 21 biomarkers from our extensive library with minimal sample volume.
Proteins
~200 Pre-validated assays
Sample
1 µL Plasma, serum & more
Olink Target 96
Target specific disease areas or key biological processes with multiplex immunoassay panels.
Proteins
1,100+ On 15 targeted panels
Sample
1 µL Plasma, serum & more
Olink Target 48
Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.
Proteins
89 On 2 panels
Sample
1 µL Plasma, serum & more